Dogwood Therapeutics Is A Biotechnology Company Focused On Developing Innovative Therapeutics For Pain And Fatigue Related Illnesseslisted On Nasdaq Under The Ticker Dwtxthe Company Has Shifted Its Focus To The Clinical Development Of Key Therapeutic Assets The Company Specializes In Two Main Areasnon Opioid Analgesics And Antiviral Therapiesits Lead Producthalneuronis A Selective Sodium Channel Blocker Aimed At Treating Moderate To Severe Chemotherapy Induced Neuropathic Pain And Other Pain Conditionsadditionallydogwood Is Developing Imc 1 And Imc 2Proprietary Combinations Of Anti Herpes Antivirals And The Anti Inflammatory Agent Celecoxibimc 1 Targets Fibromyalgiawhile Imc 2 Addresses Fatigue Associated With Long Covid Dogwood Therapeutics Is Committed To Addressing Chronic Diseases By Targeting Viral Activation And Immune Responsesutilizing A Research Strategy That Combines Antiviral And Anti Inflammatory Approaches
